PURPOSE: To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Patients with previously untreated AML or higher-risk MDS age 15 to 65 years with appropriate organ function and no core-binding factor abnormality were candidates. Induction therapy was vorinostat 500 mg orally three times a day (days 1 to 3), idarubin 12 mg/m(2) intravenously (IV) daily × 3 (days 4 to 6), and cytarabine 1.5 g/m(2) IV as a continuous infusion daily for 3 or 4 days (days 4 to 7). Patients in remission could be treated with five cycles of consolidation therapy and up to 12 months of maintenance therapy with single-agent vorinostat. The study was designed to stop early if either excess toxicity or low probability of median event-free survival (EFS) of more than 28 weeks was likely. RESULTS: After a three-patient run-in phase, 75 patients were treated. Median age was 52 years (range, 19 to 65 years), 29 patients (39%) were cytogenetically normal, and 11 (15%) had FLT-3 internal tandem duplication (ITD). No excess vorinostat-related toxicity was observed. Induction mortality was 4%. EFS was 47 weeks (range, 3 to 134 weeks), and overall survival was 82 weeks (range, 3 to 134 weeks). Overall response rate (ORR) was 85%, including 76% complete response (CR) and 9% in CR with incomplete platelet recovery. ORR was 93% in diploid patients and 100% in FLT-3 ITD patients. Levels of NRF2 and CYBB were associated with longer survival. CONCLUSION: The combination of vorinostat with idarubicin and cytarabine is safe and active in AML.
PURPOSE: To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Patients with previously untreated AML or higher-risk MDS age 15 to 65 years with appropriate organ function and no core-binding factor abnormality were candidates. Induction therapy was vorinostat 500 mg orally three times a day (days 1 to 3), idarubin 12 mg/m(2) intravenously (IV) daily × 3 (days 4 to 6), and cytarabine 1.5 g/m(2) IV as a continuous infusion daily for 3 or 4 days (days 4 to 7). Patients in remission could be treated with five cycles of consolidation therapy and up to 12 months of maintenance therapy with single-agent vorinostat. The study was designed to stop early if either excess toxicity or low probability of median event-free survival (EFS) of more than 28 weeks was likely. RESULTS: After a three-patient run-in phase, 75 patients were treated. Median age was 52 years (range, 19 to 65 years), 29 patients (39%) were cytogenetically normal, and 11 (15%) had FLT-3 internal tandem duplication (ITD). No excess vorinostat-related toxicity was observed. Induction mortality was 4%. EFS was 47 weeks (range, 3 to 134 weeks), and overall survival was 82 weeks (range, 3 to 134 weeks). Overall response rate (ORR) was 85%, including 76% complete response (CR) and 9% in CR with incomplete platelet recovery. ORR was 93% in diploid patients and 100% in FLT-3 ITD patients. Levels of NRF2 and CYBB were associated with longer survival. CONCLUSION: The combination of vorinostat with idarubicin and cytarabine is safe and active in AML.
Authors: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Y Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Hagop M Kantarjian; Harry P Erba; David Claxton; Martha Arellano; Roger M Lyons; Tibor Kovascovics; Janice Gabrilove; Michael Craig; Dan Douer; Michael Maris; Stephen Petersdorf; Paul J Shami; Andrew M Yeager; Stephen Eckert; Rekha Abichandani; Stefan Faderl Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544
Authors: Frederik Damm; Michael Heuser; Michael Morgan; Katharina Wagner; Kerstin Görlich; Anika Grosshennig; Iyas Hamwi; Felicitas Thol; Ewa Surdziel; Walter Fiedler; Michael Lübbert; Lothar Kanz; Christoph Reuter; Gerhard Heil; Ruud Delwel; Bob Löwenberg; Peter J M Valk; Jürgen Krauter; Arnold Ganser Journal: Blood Date: 2011-03-03 Impact factor: 22.113
Authors: Blanca Sanchez-Gonzalez; Hui Yang; Carlos Bueso-Ramos; Koyu Hoshino; Alfonso Quintas-Cardama; Victoria M Richon; Guillermo Garcia-Manero Journal: Blood Date: 2006-05-04 Impact factor: 22.113
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero Journal: Blood Date: 2007-06-27 Impact factor: 22.113
Authors: Guillermo Garcia-Manero; Hui Yang; Carlos Bueso-Ramos; Alessandra Ferrajoli; Jorge Cortes; William G Wierda; Stefan Faderl; Charles Koller; Gail Morris; Gary Rosner; Andrey Loboda; Valeria R Fantin; Sophia S Randolph; James S Hardwick; John F Reilly; Cong Chen; Justin L Ricker; J Paul Secrist; Victoria M Richon; Stanley R Frankel; Hagop M Kantarjian Journal: Blood Date: 2007-10-25 Impact factor: 22.113
Authors: Ken Shiozawa; Takeo Nakanishi; Ming Tan; Hong-Bin Fang; Wen-chyi Wang; Martin J Edelman; David Carlton; Ivana Gojo; Edward A Sausville; Douglas D Ross Journal: Clin Cancer Res Date: 2009-02-17 Impact factor: 12.531
Authors: Olatoyosi Odenike; Anna Halpern; Lucy A Godley; Jozef Madzo; Theodore Karrison; Margaret Green; Noreen Fulton; Ryan J Mattison; Karen W L Yee; Meghan Bennett; Gregory Koval; Gregory Malnassy; Richard A Larson; Mark J Ratain; Wendy Stock Journal: Invest New Drugs Date: 2014-12-09 Impact factor: 3.850
Authors: Daniel J DeAngelo; Alison R Walker; Richard F Schlenk; Jorge Sierra; Bruno C Medeiros; Enrique M Ocio; Christoph Röllig; Stephen A Strickland; Felicitas Thol; Sue-Zette Valera; Kohinoor Dasgupta; Noah Berkowitz; Robert K Stuart Journal: Leuk Res Date: 2019-08-01 Impact factor: 3.156